{"doi":"10.1016/j.annonc.2021.02.013","title":"Advances in cancer research dissemination through the pandemic and beyond","abstract":"The coronavirus 2019 (COVID-19) pandemic has deeply impacted biomedical research. Rapid dissemination of research findings (both clinical and laboratory-based) plays a pivotal role not just to facilitate scientific progress, but also to guide clinical decision-making in the clinic. Traditional platforms for disseminating information included the three Ps (paper, podium, and poster): first, papers published in peer-reviewed journals; second, podium oral talks; third, poster presentations at professional meetings. However, as worldwide strategies to mitigate infection transmission significantly decreased these opportunities for the traditional face-to-face contact, the scientific community had to immediately adapt and innovate to identify and deploy new research dissemination methods.1Desai A. Kuderer N.M. Lyman G.H. Crowdsourcing in crisis: rising to the occasion.JCO Clin Cancer Inform. 2020; 4: 551-554Crossref PubMed Scopus (7) Google Scholar In oncology, scientific breakthroughs, Food and Drug Administration approvals, and practice-changing studies are shared at major society meetings, such as the annual meetings of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and others. For many oncology stakeholders, these annual congresses may be their primary dedicated time away from the office for an intense immersive didactic experience to keep abreast of the field's developments. Moreover, for academia and industry colleagues, face-to-face meetings foster collaborations. With increased workload, coupled with the strain of the pandemic and meetings transitioning to an entirely virtual platform, clinicians and researchers work to identify different methods of research dissemination, recognizing this circumstance as both a challenge and opportunity given the critical importance of effective sharing of data.2Ross-Hellauer T. Tennant J.P. Banelytė V. et al.Ten simple rules for innovative dissemination of research.PLoS Comput Biol. 2020; 16: e1007704Crossref PubMed Scopus (21) Google Scholar This adaptation required researchers to consider thinking beyond traditional output formats to complement conventional research.1Desai A. Kuderer N.M. Lyman G.H. Crowdsourcing in crisis: rising to the occasion.JCO Clin Cancer Inform. 2020; 4: 551-554Crossref PubMed Scopus (7) Google Scholar Recognizing that how we share gains significance when the news cycle is very short. Here, we explore 10 ways that may improve both upstream and downstream research impact (Figure 1).1.Twitter: The role of social media platforms such as Twitter for dissemination and critique of scientific research findings increased significantly during the pandemic. The increasing use of Twitter among hematology-oncology professionals at medical conferences has been previously described.3Pemmaraju N. Mesa R.A. Majhail N.S. Thompson M.A. The use and impact of Twitter at medical conferences: best practices and Twitter etiquette.Semin Hematol. 2017; 54: 184-188Crossref PubMed Scopus (26) Google Scholar The pandemic, however, has led to novel ways of incorporating Twitter outside of medical conferences. Fabiano et al.4Fabiano N. Hallgrimson Z. Kazi S. et al.An analysis of COVID-19 article dissemination by Twitter compared to citation rates.medRxiv. 2020; https://doi.org/10.1101/2020.04.20.20061861Crossref Scopus (0) Google Scholar showed that articles on COVID-19 had significantly higher tweet rates than citation rates, highlighting the importance of social media in rapidly expanding research periods. Furthermore, increased utilization of crowdsourcing (via Twitter) for disaster response has also emerged.5Desai A. Warner J. Kuderer N. et al.Crowdsourcing a crisis response for COVID-19 in oncology.Nat Cancer. 2020; https://doi.org/10.1038/s43018-020-0065-zCrossref PubMed Scopus (47) Google Scholar This has led to the development of patient registries to answer some key questions. One such example is the COVID-19 and Cancer Consortium (CCC","journal":"Annals of Oncology","year":2021,"id":223259,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7634,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":437265,"name":"Ishwaria M. Subbiah","orcid":"0000-0002-0758-7911","position":1,"is_corresponding":false},{"id":226642,"name":"Vivek Subbiah","orcid":"0000-0002-6064-6837","position":2,"is_corresponding":false},{"id":105134,"name":"Aakash Desai","orcid":"0000-0002-2943-3817","position":0,"is_corresponding":true}],"reference_count":29,"raw_metadata":null,"created_at":"2026-07-18T23:54:11.061295Z","pmid":"33636283","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}